Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
620 people get NKTR articles and Market Currents by email alert.
Get email alerts on NKTR »
HEADLINES:
ALL
|
PRO
|
FOCUS
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
PR Newswire (May 9, 2013)
-
-
-
-
PR Newswire (Mar 1, 2013)
-
PR Newswire (Feb 28, 2013)
-
-
-
To learn more about Seeking Alpha Pro, click here.
-
-
-
-
-
Cowen Sees Nektar Outperforming Market By 30%+Notable Calls • Wed, Jun 27, 2007 -
Nektar Therapeutics: Strong Short Squeeze CandidateNotable Calls • Thu, May 10, 2007
-
-
-
-
-
-
-
-
-
-
-
-
-
-
7 Fast Growing Small Cap Biotech Stocks With Analyst ConfidenceZetaKap • Fri, Jul 6, 2012 -
-
-
-
5 Hedge Fund Biotech Stock Picks With Significant Short CoveringKapitall • Tue, Apr 24, 2012 -
-
-
Nektar CEO Discusses Q3 2010 Results - Earnings Call TranscriptThu, Nov 4, 2010
-
Nektar Therapeutics Q2 2010 Earnings Call TranscriptThu, Jul 29, 2010
-
Nektar Therapeutics Q1 2010 Earnings Call TranscriptThu, May 6, 2010
-
Nektar Therapeutics Q2 2009 Earnings Call TranscriptTue, Aug 4, 2009
-
Nektar Therapeutics F4Q08 and Year End 2008 Earnings Call TranscriptMon, Mar 2, 2009
-
Nektar Therapeutics, Q4 2008 Earnings Call TranscriptMon, Mar 2, 2009
-
Nektar Therapeutics Q3 2008 Earnings Call TranscriptThu, Nov 20, 2008
-
Nektar Therapeutics Q2 2008 Earnings Call TranscriptSat, Aug 9, 2008
-
Nektar Therapeutics Q1 2008 Earnings Call TranscriptMon, May 19, 2008
-
Nektar Therapeutics Q4 2007 Earnings Call TranscriptMon, Mar 10, 2008
-
PR Newswire (May 9, 2013)
-
PR Newswire (Mar 1, 2013)
-
PR Newswire (Feb 28, 2013)
-
PR Newswire (Nov 12, 2012)
-
PR Newswire (Aug 9, 2012)
NKTR vs. ETF Alternatives
Company Description
We are a clinical-stage biopharmaceutical company developing a pipeline of drug candidates that utilize our PEGylation and advanced polymer conjugate technology platforms, which are designed to improve the benefits of drugs for patients. Our current proprietary product pipeline is comprised of... More
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
- Thursday, May 9, 5:36 PM Nektar (NKTR): Q1 EPS of -$0.48 misses by $0.06. Revenue of $23M misses by $3.3M. (PR) Comment! [Earnings, Breaking News, Healthcare]
- Tuesday, April 16, 7:25 AM Bayer initiates Phase III clinical trial of BAY41-6551, a treatment for Gram-negative pneumonia the company is developing with Nektar Therapeutics (NKTR). Comment! [Healthcare]
- Thursday, February 28, 5:27 PM Nektar Therapeutics (NKTR): Q4 EPS of -$0.46 misses by $0.01. Revenue of $21.1M beats by $2.1M. (PR) Comment! [Earnings, Breaking News, Healthcare]
- Tuesday, February 26, 8:31 AM AstraZeneca (AZN) says there were "no reports of opioid withdrawal" that could be attributed to its Naloxegol laxative in a fourth Phase III trial. AZN and partner Nektar Therapeutics (NKTR) will use the outcome to obtain decontrol of naloxegol, which is considered a Schedule II controlled substance by the DEA. With the testing demonstrating other "high-level" safety results, AstraZeneca plans to file for FDA and EU approval of Naloxegol in Q3. (PR) 1 Comment [Healthcare]
- Monday, February 25, 7:28 AM Affymax (AFFY) prints at $3.41 premarket, -78.8%, following yesterday's report of the Omontys recall. AFFY has no other late-stage drugs in its pipeline. Piper expects shares to trade to cash value (~$2) "as investors take into account the lack of visibility." In play: AMGN, whose Epogen dominates the antianemia market (+2.4%), NKTR (which earns royalties on Omontys sales), and FMS, which pulled a trial two weeks ago (-1.3%). Comment! [Healthcare, On the Move]
- Tuesday, January 15, 1:33 PM Nektar Therapeutics (NKTR +5.4%) gets a big boost out of Lazard Capital today, after it initiated the drug developer with a Buy rating and a price target of $15 a share. The company has a solid pipeline with a number of drugs on its docket, including Naloxegol, which has just finished Phase III testing, Cipro DPI with Bayer in Phase III and Baxter 855 and Amikacin Inhale preparing for Phase III. Royalties on these products alone are capable of generating over $750M a year. Comment! [Healthcare, On the Move]
-
Wednesday, January 9, 5:22 PM
After-hours top gainers, as of 5:15 p.m.: VOXX +15%. NEWL +9%. SQNM +6%. PSMT +6%. XCO +6%.
After-hours top losers: QUIK -9%. RT -9%. HAFC -7%. NKTR -7%. HALO -7%. 1 Comment [On the Move] - Tuesday, November 13, 2012, 9:33 AM The Street's Adam Feuerstein wonders whether AstraZeneca's (AZN) and Nektar's (NKTR) critical naloxegol product for opioid-induced constipation failed one of its Phase III trials rather than passed it, as the companies indicate. Feuerstein's skepticism is based on AZN retrieving data from one patient that was thought to be non-retrievable after the database for the trial had been locked. 1 Comment [Healthcare]
- Tuesday, November 13, 2012, 12:10 AM Notable earnings after Tuesday’s close: CSCO, GA, IAG, NKTR, RENN, SVM Comment! [Earnings]
- Monday, November 12, 2012, 5:35 PM Notable earnings after Tuesday’s close: CSCO, GA, IAG, NKTR, RENN, SVM Comment! [Earnings]
- Monday, November 12, 2012, 12:45 PM Midday top 10 gainers: TIE +42%. STV +32%. MYRX +18%. CPSS +17%. PZZI +15%. SRPT +13%. EVI +13%. JEF +12%. GILD +12%. CXS +12%. Midday top 10 Losers: CLVS -33%. GALE -33%. STSI -23%. RECV -17%. BZH -15%. ET -14%. XIDE -13%. NKTR -12%. MEET -12%. IDN -11%. Comment!
- Monday, November 12, 2012, 10:04 AM Astrazeneca's (AZN) naloxegol product for treating opioid-induced constipation (OIC) performed well in two Phase III trials and one safety extension study. The trials also brought on no imbalances in serious adverse events. Astrazeneca acquired the worldwide licence for naloxegol from its developer, Nektar Therapeutics (NKTR -0.1%), in 2009. (PR) Comment! [Healthcare]
-
Monday, November 12, 2012, 9:10 AM
Premarket gainers: TIE +43%. JEF +24%. MYRX +17%. CXS +15%. GILD +12%. CELG +10%. SVNT +7%. SQNM +7%. LUK +7%. RIMM +6%. NKTR +6%. STV +5%. DNDN +5%. CEL +5%. PCP +5%.
Losers: CLVS -41%. STSI -20%. NBG -11%. Comment! [On the Move] - Thursday, November 1, 2012, 12:10 AM Notable earnings after Thursday’s close: AIG, AIV, ALSK, ATML, BKD, BMR, CAR, CENX, CHK, DCT, DDR, DWA, EIX, EQIX, FLR, FSLR, GLUU, HAIN, HIG, HTGC, INT, ITMN, JMBA, JOE, KERX, KOG, LIFE, LLNW, LNC, LNKD, LVS, MDLZ, MELI, MNKD, NEM, NGD, NKTR, NLY, OMPI, ONNN, ONXX, OPEN, PBI, PCLN, ROVI, RSG, SAM, SBUX, SHO, SKUL, SPWR, SWKS, SWN, TRIP, UNTD, VNO, VRTX, WBMD, WIT, WPRT, YELP, ZAGG, ZIOP Comment! [Earnings]
- Wednesday, October 31, 2012, 5:35 PM Notable earnings after Thursday’s close: AIG, AIV, ALSK, ATML, BKD, BMR, CAR, CENX, CHK, DCT, DDR, DWA, EIX, EQIX, FLR, FSLR, GLUU, HAIN, HIG, HTGC, INT, ITMN, JMBA, JOE, KERX, KOG, LIFE, LLNW, LNC, LNKD, LVS, MDLZ, MELI, MNKD, NEM, NGD, NKTR, NLY, OMPI, ONNN, ONXX, OPEN, PBI, PCLN, ROVI, RSG, SAM, SBUX, SHO, SKUL, SPWR, SWKS, SWN, TRIP, UNTD, VNO, VRTX, WBMD, WIT, WPRT, YELP, ZAGG, ZIOP Comment! [Earnings]
- Tuesday, September 18, 2012, 10:17 AM Nektar Therapeutics (NKTR +2.1%) says that a Phase 1a clinical study of its drug candidate NKTR-192, a short-acting mu-opioid analgesic for the treatment of acute pain, achieved its target pharmacokinetic profile. The company also says that dosing has commenced in a second Phase 1a clinical study which will explore the pharmacodynamic profile of the drug in healthy subjects. Comment! [Healthcare, On the Move]
-
Jim Van Meerten
NKTR - 96% Barchart technical buy signal - 15 new highs and up 26.27% in the last month - Relative strength Index 77.91% - View all 0 replies
-
- View all 0 replies
-
reachmygoals1
Nektar's(NKTR) upcoming catalysts: * NKTR-102 - Phase 2 expansion top-line data in ovarian cancer (April) * NKTR-181 - Phase 2 start - View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
Ryan Mallory
5 Trade Setups While Waiting For The Market To Do Something http://stk.ly/pcW4WG BEBE GMO LIOX MHGC NKTR - View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
LATEST REPLIES